Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …

Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T
cells. Although successful in treatment of hematologic malignancies, CAR T cells are …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface
antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen …

The interaction between programmed cell death protein 1 (PD-1) on activated T cells and its
ligands on a target tumour may limit the capacity of chimeric antigen receptor (CAR) T cells …

Mesothelin is a tumor antigen that is highly expressed in many human cancers, including
malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an …